New drug cocktail shows promise against aggressive breast cancer
NCT ID NCT01796197
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of chemotherapy (paclitaxel) and two targeted antibodies (trastuzumab and pertuzumab) given before mastectomy to 23 women with HER2-positive inflammatory breast cancer. The goal was to see if the treatment could wipe out all cancer in the breast and lymph nodes by the time of surgery. Results showed that some women had a complete response, meaning no cancer remained, and the approach may help lower the chance of recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide
What this could lead to
If successful, this combination could improve the chance of eliminating all cancer before surgery and reduce the risk of the cancer coming back.
What could go wrong
This is a small, early-phase trial with only 23 participants. The drugs may cause side effects like heart problems, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States